Significant acceptances by SCHWARZ shareholders for UCB tender offer
The final total of acceptances received by midnight on Friday December 8 will be available on Thursday December 14, 2006. Acceptances already counted show UCB has received tenders in excess of 76% of the fully diluted share capital of SCHWARZ PHARMA. As is required in such a transaction in Germany, the offer will be extended for an additional two weeks.
Roch Doliveux, CEO of UCB, said, "I am delighted with the results of the tender offer so far. The current level of acceptances already received from SCHWARZ shareholders will allow the two companies to capture significant benefits of this exciting business combination, on which our resources will be focused. I thank shareholders for their support in building UCB as the next generation biopharmaceutical leader."
Most read news
Other news from the department business & finance

Get the chemical industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.